Cardiovascular Systems CSII, a medical device company
developing and commercializing innovative interventional treatment systems for
vascular disease, today announced publication of 12-month results from its
CALCIUM 360° study in the Journal of Endovascular Therapy, August 2012.
CALCIUM 360° is a prospective, randomized, multi-center study of 50 patients
(64 lesions), comparing one-year safety and efficacy of CSI's Diamondback 360°
atherectomy device followed by percutaneous transluminal angioplasty (PTA),
versus PTA alone, to treat calcified infrapopliteal lesions in patients with
critical limb ischemia.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in